The 17th JFCR-ISCC

December 5 (Wed)- 6 (Thu), 2012
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan

The 17th JFCR-International Symposium on Cancer Chemotherapy (JFCR-ISCC) is scheduled as indicated above. I sincerely welcome your participation in this Symposium.

The JFCR-ISCC aims at information exchange on the latest findings of newly developing molecular-targeted anti-cancer drugs and the related topics. Molecular-targeted anti-cancer drugs have been developing prominently with global standards. Meanwhile, already launched molecular-targeted drugs have often been faced with rather quickly acquired resistance, and various challenges against the resistance are rapidly evolving. Accessing to these information is indispensable, moreover, informal exchanges of personal, very specific, or even unsuccessful experiences, are critically valuable for effective achievements of drug development. I believe the JFCR-ISCC with relatively small size will provide you an excellent opportunity for such communication through personal contacts.

In the upcoming 17th JFCR-ISCC, mechanisms of drug resistance and their conquest are the main topics. I hope the Symposium would be an excellent occasion for you to access the domestic and international developments of new anticancer drugs and also to meet scientists, clinicians, and drug developers.

Looking forward to seeing you in Tokyo,

Mitsuaki Yoshida, Ph.D.
Chairman, JFCR-ISCC
Director, Cancer Chemotherapy Center, JFCR

(*Program update)


Poster Download

 

To attend the Luncheon Seminars, please receive Luncheon Seminar Ticket at “Luncheon Ticket Desk” . The desk will open from 11:00 on December 5.

The 17th Symposium Program Committee

Naoya Fujita (Program Committee Chairman, Cancer Chemotherpy Ctr.)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)
Kiyohiko Hatake (Cancer Chemotherpy Ctr.)
Manabu Kawada (Inst. Microbial Chem.)
Kei Muro (Aichi Cancer Ctr. Hospital)
Atsushi Ohtsu (National Cancer Ctr. Hospital East)
Isamu Okamoto (Kinki Univ.)
Hiroyuki Seimiya (Cancer Chemotherpy Ctr.)
Toshimitsu Uenaka (Eisai Co., Ltd)
Kazuhito Yamamoto (Aichi Cancer Ctr. Hospital)
Seiji Yano (Kanazawa Univ.)

December 5

11:00-13:00

Poster mounting

12:00

Committee Meeting

Opening remark

13:00-13:10

Mitsuaki Yoshida (Cancer Chemotherapy Center)

Opening remark

IPatient Selection Strategies in Early Clinical Studies

Chairpersons: Anthony W. Tolcher and Atsushi Ohtsu

13:10-13:40

Jaap Verweij (Erasmus University Medical Center)

The future of early clinical trials in new drug development

13:40-14:00

Toshio Shimizu (Kinki University)

Personalizing cancer treatment of targeting of PI3K/AKT/mTOR pathway in patients with advanced cancer

14:00-14:10

Discussion

14:10-14:30

Coffee break

II Companion Diagnostics

Chairpersons: Gregory K. Pennock and Yoshikazu Sugimoto

14:30-15:00

Mark J. Ratain (The University of Chicago)

Companion diagnostics: Consideration of tumor heterogeneity

15:00-15:20

Kengo Takeuchi (Cancer Institute, JFCR)

Discovery of novel fusion genes by histomolecular pathology

15:20-15:30

Discussion

Poster Session

15:30-16:30

P1

Naoki Kaneko (Astellas Pharma Inc.)

Sepantronium bromide (YM155), a survivin suppressant, enhances the antitumor effect of rituximab in diffuse large B cell lymphoma (DLBCL).

P2

Osamu Tohyama (Eisai Co. Ltd.)

Preclinical effect of lenvatinib on human thyroid cancer targeting angiogenesis and receptor tyrosine kinase signaling

P3

Hisato Kawakami (Kinki University)

MET amplification as a potential therapeutic target in gastric cancer

P4

Nozomu Fuse (National Cancer Center Hospital East)

Results of phase I study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor

P5

Takayuki Nakagawa (Kanazawa University)

Circumvention of EGFR-TKI resistance associated with BIM polymorphism

P6

Hiromichi Ebi (Kanazawa University)

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

P7

Sho Isoyama (Cancer Chemotherapy Center)

Identification of IGF1R as a responsible factor for acquired resistance to PI3K inhibitors

P8

Yasuhiro Hama (Daiichi Sankyo Co., Ltd.)

Effect of DS-7423, a novel dual PI3K/mTOR inhibitor, on tumor growth and FDG uptake

P9

Daisuke Tatsuda (Institute of Microbial Chemistry, Numazu)

Inhibition of p53-Mdm2 interaction by ellagitannins

P10

Makoto Hasegawa (Nagahama Institute of Bio-Science and Technology

Identification of SAP155 as the target protein of GEX1A (herboxidiene), a pre-mRNA spricing inhibitor.

P11

Akiyoshi Komuro (University of Tokyo)

BMP4 suppresses tumorigenic activity of glioma-initiating cells through loss of stemness properties

P12

Yoshimi Ohashi (Cancer Chemothrapy Center)

A novel golgi disruptor, AMF-26, targets ADP-ribosylation factor 1 (Arf1) with potential for Cancer therapy

 

 

17:00

Mixer

December 6

III Cancer Cell Line Panels for Drug Screening

Chairpersons: Michael Kahn and Toshimitsu Uenaka

9:00-9:30

Cyril H. Benes (MGH Cancer Center)

Systematic identification of genomic markers of drug sensitivity in cancer cells

9:30-9:50

Takao Yamori (Pharmaceuticals and Medical Devices Agency, Japan)

JFCR39 cell line panel

9:50-10:00

Discussion

10:00-10:20

Coffee break

Poster Discussion Session

Chairperson: Shiro Akinaga

10:20-10:50

Mentor: Dr. Jaap Verweij

Poster #: P1-P4

10:50-11:20

Mentor: Dr. Mark J. Ratain

Poster #: P5-P8

11:20-11:50

Mentor: Dr. Keith T. Flaherty

Poster #: P9-P12

ILuncheon Seminar

Chairperson: Akihiko Tsuruoka

12:00-12:45

Bruce A. Littlefield (Oncology PCU, Eisai Inc.)

Preclinical discovery, pharmacology, and mechanism of eribulin

IILuncheon Seminar

Chairperson: Toshimitsu Uenaka

12:00-12:45

Felix Garzon (Oncology PCU, Eisai Inc.)

Clinical development of eribulin

 

To attend the Luncheon Seminars, please receive Luncheon Seminar Ticket at “Luncheon Ticket Desk” . The desk will open from 11:00 on December 5.

 

13:00-16:00

Poster removal

Special Lecture

Chairperson : Tetsuichiro Muto

13:00-13:40

Jeffrey A. Engelman (MGH Cancer Center)

Resistance to EGFR-TKI in lung cancer

IV Revival of Immune Response or BRAF Inhibition for Cancer Therapy

Chairpersons: Keith T. Flaherty and Ryuzo Ueda

13:40-14:10

Gregory K. Pennock (M.D. Anderson Cancer Center)

Ipilimumab: A novel immunopotentiator

14:10-14:40

Keith T. Flaherty (MGH Cancer Center)

BRAF inhibition as a basis for building combination targeted therapy in melanoma and other cancers

14:40-14:50

Discussion

14:50-15:10

Coffee break

V Targeting FGFR Pathway

Chairpersons: Jeffrey A. Engelman and Saburo Sone

15:10-15:40

Ken Kobayashi (Janssen Pharmaceutical K.K.)

FGFR tyrosine kinase inhibitor

15:40-16:10

Anthony W. Tolcher (START, San Antonio)

Targeting FGR ligands in cancer with the FGF Trap FP 1039

16:10-16:20

Discussion

VI New Drugs under Clinical Trials

Chairpersons: Cyril H. Benes and Shunji Takahashi

16:20-16:50

Glenn Begley (TetraLogic Pharmaceuticals)

IAP binding peptide (Birinapant (TL32711)(SMAC mimetics))

16:50-17:20

Michael Kahn (University of Southern California)

Pharmacologic manipulation of stem cells and cancer stem cells

17:20-17:30

Discussion

Closing remark

17:30-17:40

Jaap Verweij

Closing Remark

Page TOP